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Abstract. Salivary gland tumours (SGT) constitute a diag-
nostically challenging group of neoplasms with frequently
unpredictable clinical outcome. The proliferation rate facili-
tates the identification of aggressive SGT. The Chromatin
Assembly Factor-1 (CAF-1) is a major epigenetic regulator
of nuclear chromatin organization during DNA replication. It
plays a critical function in human tumourigenesis and has
been proposed as a new proliferation and prognostic marker
for some malignancies. This study focused on the role of
CAF-1/p60 protein as a marker of clinical value for SGT.
The expression of CAF-1/p60 was evaluated by immunohisto-
chemistry on a retrospective series of 362 surgically excised
benign and malignant SGT with different histogenesis and,
when available, on fine-needle pre-surgical cytological
biopsies. The resulting data were compared with traditional
prognostic parameters, including the expression of the routine
proliferation marker ki67/MIB1. CAF-1/p60 was detectable
in all SGT, with highest degree of expression in metastasizing
malignant tumours. Moreover, the cases of benign tumours
which progressed to carcinoma during the follow-up, showed
significantly higher CAF-1/p60 expression than non-
progressing benign SGT, both on histological sections and
cytological smears of the primary tumour. Cox's multiple
regression analysis selected CAF-1/p60 expression as the
best independent predictor of cancer development for benign
SGT (p<0.0001), and the best independent predictor of
metastasis onset for malignant tumours (p<0.0004). Over-
expression of CAF-1/p60, on histological and/or cytological
samples, characterizes malignant SGT with aggressive
behaviour, irrespective of their specific histotype, and allows
the early diagnosis of progression toward malignancy of
morphologically benign tumours.
Introduction
Salivary gland tumours (SGT) constitute morphologically
and biologically heterogeneous neoplasms, which give rise to
significant diagnostic and management challenges (1-3).
These tumours are rare, with an overall incidence of 0.5-
3.0 cases per 100000 per year. Malignant SGT accounts for
about 0.5% of all malignancies and for 3-6% of head and
neck cancers (1).
Many studies attempted to better define the prognosis of
these tumours (4-6). However, the available markers are unable
to ultimately discriminate, among benign SGT, the cases that
will give rise to progression toward malignancy, and, for
malignant SGT, the cases with a metastasizing behaviour.
Cell proliferation rate has been proposed as an useful
adjunctive tool for predicting the outcome of SGT, but there
is not a definitive agreement between researchers on the best
proliferation-associated prognostic marker for these tumours
(3,4,6-12).
The orderly progression of the cell cycle is governed by
epigenetic modifications, mostly concerning the hierarchical
assembly and remodelling of chromatin, which are regulated
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by various Assembly Factors (13,14). Among these, the
Chromatin Assembly Factor-1 (CAF-1), a heterotrimeric
complex, composed of the histone-chaperone proteins p48,
p60 and p150, is the most powerful discriminator between
the proliferative and the quiescent state (15-17). CAF-1/p60
has been recently proposed as a new sensitive marker of cell
proliferation, able to predict the prognosis of some human
cancer types (18-20).
We have performed a study on a retrospective series of
benign and malignant SGT, with the aim to establish whether
the immunohistochemical expression of CAF-1/p60 protein
may have a value in discriminating SGT with different
clinical behaviour, beyond the available prognostic para-
meters including the routinely assessed proliferation marker
ki67/MIB1.
Materials and methods
Selection of cases. The study population was selected among
the patients diagnosed with SGT at the Federico II University
of Naples, Italy, from April 1993 to March 2008.
Only the cases of patients treated primarily with surgery,
with healthy surgical margins distant from the tumour by at
least 1 cm, and with clinical follow-up data not less than 12
months, were considered for the study.
Patients characteristics, the anatomic site and histotype of
primary tumours and, for malignant SGT, the degree of diffe-
rentiation and tumour stage were collected and recorded in a
data base (21,22).
Immunohistochemistry. Immunohistochemical analysis was
performed on 4-µm thick serial sections, mounted on poly-L-
lysine coated glass slides. Sections were deparaffinized, and
underwent antigen retrieval by microwave oven treatment
(5 min x 3 times, in 1% sodium citrate buffer, pH 6.0); non-
specific bindings were blocked by incubation (2 h at room
temperature) with 1.5 % non-immune mouse serum (1:20,
Dakopatts, Hamburg, Germany). Endogenous peroxidases
were quenched with 0.3% hydrogen peroxide in methanol;
slides were rinsed twice with Tris-HCl buffer, and incubated
overnight at 4˚C with anti-CAF-1/p60 antibody (SS53-
ab8133, Abcam, Cambridge, MA, USA, diluted 1:300) and
ki67/MIB1 antibody (MIB1, Dako A/S, Glostrup, Denmark,
diluted 1:200) (19,20,23).
The standard streptavidin-biotin linked horseradish
peroxidase (LSAB) technique using the Dako (LSAB kit
HRP, Carpinteria, CA) was then performed, with the 3,3'-
diaminobenzidine (DAB, Vector Laboratories Inc.,
Burlingame, CA, USA) being used as a substrate chromogen
solution for the development of the peroxidase activity.
After nuclear counterstaining with Mayer's haematoxylin for
30 sec, sections were mounted and cover-slipped with a
synthetic medium.
For each run, positive controls were performed on
sections of breast carcinomas for CAF-1/p60, and on small
bowel samples for ki67/MIB1. For negative controls, non-
immune serum in TBS buffer (1:500) was used instead of
the two primary antibodies. The cells with a definite brown
nuclear staining were judged as positive for both the anti-
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Table I. Clinical and pathological features, CAF-1/p60 and ki67/MIB1 immunohistochemical expression in 268 cases of
benign SGT.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Characteristics Total (%) CAF-1/p60 (quickscore) ki67/MIB1 (quickscore)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
5 (2+3) 6 (3+3) 3 (1+2) 4 (2+2) 5 (2+3)
No. of subjects
Male 116 43.28 114 (42.53) 2 (0.75) 100 (37.31) 8 (2.99) 8 (2.99)
Female 152 56.72 150 (55.97) 2 (0.75) 131 (48.69) 12 (4.48) 9 (3.36)
Age
Average (range) 39.83 (9-80) - - - - -
Disease site
Parotid gland 203 75.75 200 (74.63) 3 (1.12) 180 (67.16) 12 (4.48) 11 (4.11)
Submandibular gland 33 12.31 33 (12.31) 0 30 (11.20) 2 (0.75) 1 (0.37)
Sublingual gland 1 0.4 1 (0.37) 0 1 (0.37) 0 0
Minor salivary gland 31 11.57 30 (11.20) 1 (0.37) 20 (7.46) 6 (2.23) 5 (1.87)
Histotype
BCA 3 1.12 3 (1.12) 0 3 (1.12) 0 0
PA 261 97.39 258 (96.27) 3 (1.12) 226 (84.33) 19 (7.09) 16 (5.97)
Atypical PA 4 1.49 3 (1.12) 1 (0.37) 2 (0.75) 1 (0.37) 1 (0.37)
Evolution to carcinoma ex-PA
No 263 98.13 263 (98.14) 0 230 (85.82) 18 (6.72) 15 (5.59)
Yes 5 1.87 1 (0.37) 4 (1.49) 1 (0.37) 2 (0.75) 2 (0.75)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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bodies. The immunohistochemical expression was evaluated
semi-quantitatively and scored according to the ‘quickscore‘
method, which takes into consideration either the percentage
of immunostained neoplastic cells throughout the entire tumour
section (scores 1-6: 1, 0-4%; 2, 5-19%; 3, 20-39%; 4, 40-
59%; 5, 60-79%; 6, 80-100%), termed ‘category A’, and the
staining intensity (scores 0-3, corresponding to negative, weak,
intermediate and strong staining), termed ‘category B’ (24).
The evaluation was performed independently by two expert
pathologists (S.S. and M.M.), unaware of patients' clinical
status. Discordant cases were discussed and resolved by
consensus.
For 23 cases of benign tumours, pre-surgical PAP-stained
slides of the fine-needle aspiration biopsy (FNAB) cyto-
logical samples, used for morphological diagnosis, were also
available, and were re-used for the immunostaining with
CAF-1/p60 protein, according to the technique described in
literature (Table I) (25).
Statistical analysis. Data were analyzed with SPSS package
for Windows (release 13.0). The intra- and inter-observer
agreement of the evaluation of the CAF-1/p60 and ki67/
MIB1 quickscore was calculated by k-statistics: a K co-
efficient >0.75 indicated excellent reproducibility; a K-value
between 0.4 and 0.75 denoted moderate reproducibility, and
a K-value <0.4 denoted marginal or poor reproducibility
(26).
To evaluate the prognostic value of CAF-1/p60 expression
with respect to conventional parameters and ki67/MIB1
expression, a univariate analysis was performed by Kaplan-
Meier plots for each variable. The significant level was set at
p<0.05. To verify whether variables were univariately related
to our end-points (development of malignant tumour in patients
with benign cancer baseline and disease-free interval in
patients with malignant tumours baseline) curves were com-
pared by the log-rank test or the t-test for trend, when two or
three curves had to be compared, respectively.
In order to establish whether CAF-1/p60 expression
contributed to a better definition of the prognosis of patients,
after the conventional data had been taken into account, a
multiple regression analysis according to the Cox's propor-
tional hazard model was performed.
The clinical usefulness of prognostic indices predicting
the risk for cancer development in patients who had a
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Figure 1. Immunohistochemical expression of CAF-1/p60 in benign SGT (LSAB-HRP, nuclear counterstaining with haematoxylin). Focal and weak nuclear
immunostaining for CAF-1/p60 in BCA (A, x106) and PA (B, x150). Higher expression of CAF-1/p60 in two cases of PA (ordinary type: C, x200; D, x250
and atypical: E, x250; F, x400) which progressed to CXPA during follow-up; PA progressed to CXPA (PAP-stained FNAB: G, x250; CAF-1/p60
immunostaining: H, x400).
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Table II. Clinical and pathological features, CAF-1/p60 and ki67/MIB1 immunohistochemical expression in 94 cases of
malignant SGT.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient CAF-1/p60 ki67/MIB1
no. Gender Age Diagnosis Gland (quickscore) (quickscore) F-UP Stage
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 M 49 PLGC Minor salivary gland 6 (3+3) 3 (1+2) 26 pT1N0M0
2 F 54 PLGC Parotid 8 (5+3) 3 (1+2) 60 R (34) pT1NxM0
3 F 13 AC Parotid 7 (4+3) 4 (2+2) 74 pT1NxM0
4 F 33 AC Parotid 6 (3+3) 4 (2+2) 67 pT3N0M0
5 M 45 AC Parotid 7 (4+3) 4 (2+2) 70 pT2NxM0
6 F 47 AC Parotid 6 (3+3) 4 (2+2) 42 pT1NxM0
7 F 78 AC Minor salivary gland 7 (4+3) 4 (2+2) 44 pT3NxM0
8 F 41 AC Parotid 7 (4+3) 4 (2+2) 20 pT1N0M0
9 F 57 AC Parotid 6 (3+3) 4 (2+2) 93 pT1NxM0
10 M 52 AC Parotid 8 (5+3) 4 (2+2) 150 R (40,142) pT1NxM0
11 M 55 AC Parotid 6 (3+3) 4 (2+2) 158 pT1N0M0
12 F 19 AC Submandibolar gland 6 (3+3) 4 (2+2) 142 pT1NxM0
13 F 57 AC Parotid 6 (3+3) 4 (2+2) 180 pT2NxM0
14 M 50 AC Parotid 6 (3+3) 4 (2+2) 110 pT2NxM0
15 F 17 AC Parotid 7 (4+3) 4 (2+2) 167 pT1NxM0
16 M 60 AC Parotid 7 (4+3) 4 (2+2) 192 pT2NxM0
17 F 23 ACC Submandibolar gland 7 (4+3) 4 (2+2) 97 pT1NxM0
18 F 34 ACC Minor salivary gland 7 (4+3) 5 (2+3) 82 pT1NxM0
19 F 39 ACC Parotid 6 (3+3) 6 (3+3) 29 pT2N0M0
20 F 41 ACC Submandibolar gland 7 (4+3) 6 (3+3) 54 pT3N0M0
21 M 48 ACC Minor salivary gland 9 (6+3) 6 (3+3) 71 M (58) R (33) pT4aNxM0
22 F 56 ACC Minor salivary gland 8 (5+3) 6 (3+3) 34 pT4bNxM1
23 F 63 ACC Minor salivary gland 7 (4+3) 4 (2+2) 44 pT2NxM0
24 F 41 ACC Submandibolar gland 6 (3+3) 4 (2+2) 141 pT3N0M0
25 F 74 ACC Minor salivary gland 6 (3+3) 4 (2+2) 181 pT2NxM0
26 F 49 ACC Submandibolar gland 7 (4+3) 5 (2+3) 12 pT2N0M0
27 F 49 ACC Minor salivary gland 7 (4+3) 6 (3+3) 173 pT2NxM0
28 F 69 ACC Minor salivary gland 7 (4+3) 6 (3+3) 84 pT2NxM0
29 F 48 ACC Minor salivary gland 8 (5+3) 6 (3+3) 193 R (61) pT1NxM0
30 M 63 ACC Minor salivary gland 6 (3+3) 5 (2+3) 41 pT4aNxM0
31 M 49 ACC Minor salivary gland 6 (3+3) 6 (3+3) 170 pT1NxM0
32 M 59 ACC Minor salivary gland 8 (5+3) 5 (2+3) 185 pT2N0M0
33 M 69 ACC Minor salivary gland 6 (3+3) 6 (3+3) 16 pT1NxM0
34 F 56 ACC Submandibolar gland 7 (4+3) 4 (2+2) 177 pT2NxM0
35 F 69 ACC Minor salivary gland 7 (4+3) 4 (2+2) 181 pT1NxM0
36 M 50 ACC Parotid 8 (5+3) 4 (2+2) 177 pT3N2bM0
37 F 33 ACC Minor salivary gland 6 (3+3) 4 (2+2) 34 pT1NxM0
38 F 20 Low-grade MEC Parotid 6 (3+3) 4 (2+2) 49 pT1N0M0
39 M 34 Low-grade MEC Parotid 7 (4+3) 5 (2+3) 137 pT1N1M0
40 F 57 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 173 pT3N0M0
41 M 14 Low-grade MEC Minor salivary gland 6 (3+3) 5 (2+3) 128 pT1NxM0
42 F 18 Low-grade MEC Parotid 6 (3+3) 4 (2+2) 92 pT2N0M0
43 M 37 Low-grade MEC Parotid 6 (3+3) 4 (2+2) 129 pT1NxM0
44 F 38 Low-grade MEC Parotid 6 (3+3) 4 (2+2) 57 pT1N0M0
45 F 40 Low-grade MEC Parotid 6 (3+3) 4 (2+2) 69 pT4aN0M0
46 F 42 Low-grade MEC Parotid 7 (4+3) 4 (2+2) 127 pT1NxM0
47 M 55 Low-grade MEC Minor salivary gland 7 (4+3) 4 (2+2) 107 pT1NxM0
48 F 62 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 103 pT3NxM0
49 M 74 Low-grade MEC Minor salivary gland 6 (3+3) 5 (2+3) 129 pT1NxM0
50 M 63 Low-grade MEC Minor salivary gland 6 (3+3) 5 (2+3) 33 pT1NxM0
51 F 60 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 12 pT1NxM0
52 F 49 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 12 pT1NxM0
53 F 42 Low-grade MEC Parotid 6 (3+3) 5 (2+3) 128 pT1NxM0
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baseline benign tumour or the risk of an adverse event
(recurrence or metastasis) in patients who had a baseline
malignant tumour was calculated. Sensitivity and specificity
of prognostic indices were computed according to standard
formula. Receiver operating characteristic (ROC) curves were
drawn and areas under the curve were calculated, to evaluate
the discriminatory ability of each parameter, as follow: <0.7,
no discrimination; 0.71-0.79, acceptable; 0.8-0.89, excellent;
≥0.9, outstanding discrimination (27).
Results
The selected study population consisted of a cohort of 362
SGT (268 benign and 94 malignant).
Benign SGT. Benign tumours were composed of 265 PA, 4
of which with atypical/‘bizarre’ cells, and 3 cases of mono-
morphic (basal cell) adenomas. The clinical features of patients
are reported in Table I.
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Table II. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient CAF-1/p60 ki67/MIB1
no. Gender Age Diagnosis Gland (quickscore) (quickscore) F-UP Stage
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
54 F 40 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 162 pT2NxM0
55 M 39 Low-grade MEC Minor salivary gland 6 (3+3) 5 (2+3) 199 pT1NxM0
56 F 37 Low-grade MEC Minor salivary gland 6 (3+3) 5 (2+3) 20 pT1NxM0
57 M 49 Low-grade MEC Parotid 7 (4+3) 5 (2+3) 96 pT1NxM0
58 F 64 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 18 pT1NxM0
59 F 33 Low-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 197 pT1NxM0
60 M 39 Intermediate-grade MEC Parotid 8 (5+3) 5 (2+3) 140 R (48) pT2N0M0
61 F 51 Intermediate-grade MEC Minor salivary gland 9 (6+3) 6 (3+3) 132 M (16) pT2N2bM0
62 M 57 Intermediate-grade MEC Minor salivary gland 8 (5+3) 6 (3+3) 94 R (12) pT1NxM0
63 M 72 Intermediate-grade MEC Minor salivary gland 7 (4+3) 6 (3+3) 31 pT1NxM0
64 F 74 Intermediate-grade MEC Minor salivary gland 6 (3+3) 6 (3+3) 95 pT1NxM0
65 F 80 Intermediate-grade MEC Minor salivary gland 6 (3+3) 6 (3+3) 97 pT3NxM0
66 M 26 Intermediate-grade MEC Parotid 6 (3+3) 5 (2+3) 23 pT1N0M0
67 M 60 Intermediate-grade MEC Parotid 6 (3+3) 5 (2+3) 34 pT2N0M0
68 M 50 Intermediate-grade MEC Minor salivary gland 6 (3+3) 6 (3+3) 12 pT1NxM0
69 M 88 Intermediate-grade MEC Minor salivary gland 7 (4+3) 6 (3+3) 12 pT1NxM0
70 M 77 Intermediate-grade MEC Minor salivary gland 7 (4+3) 5 (3+2) 170 pT3N0M0
71 M 62 Intermediate-grade MEC Minor salivary gland 7 (4+3) 5 (3+2) 45 pT1NxM0
72 F 54 Intermediate-grade MEC Parotid 6 (3+3) 5 (3+2) 12 pT1NxM0
73 F 59 Intermediate-grade MEC Parotid 6 (3+3) 5 (3+2) 14 pT1NxM0
74 M 56 High-grade MEC Minor salivary gland 8 (5+3) 6 (3+3) 131 R (75) pT2N0M0
75 F 32 High-grade MEC Parotid 7 (4+3) 5 (2+3) 200 pT4NxM0
76 F 33 High-grade MEC Minor salivary gland 7 (4+3) 5 (2+3) 23 pT1NxM0
77 F 37 High-grade MEC Minor salivary gland 6 (3+3) 6 (3+3) 21 pT1NxM0
78 M 46 High-grade MEC Minor salivary gland 8 (5+3) 6 (3+3) 126 M (13) pT2N1M0
79 F 47 High-grade MEC Minor salivary gland 7 (4+3) 6 (3+3) 23 pT2NxM0
80 M 51 High-grade MEC Sublingual gland 7 (4+3) 6 (3+3) 72 pT2N0M0
81 F 58 High-grade MEC Parotid 8 (5+3) 6 (3+3) 39 M (2) pT3N2M0
82 M 60 High-grade MEC Submandibolar gland 6 (3+3) 6 (3+3) 117 pT3NxM0
83 F 41 High-grade MEC Minor salivary gland 7 (4+3) 6 (3+3) 12 pT1NxM0
84 F 78 High-grade MEC Sublingual gland 7 (4+3) 6 (3+3) 142 pT2NxM0
85 F 27 High-grade MEC Minor salivary gland 7 (4+3) 6 (3+3) 155 pT1NxM0
86 M 60 High-grade MEC Parotid 6 (3+3) 6 (3+3) 34 pT3N0M0
87 F 56 CXPA Minor salivary gland 7 (4+3) 6 (3+3) 23 pT2NxM0
88 M 19 CXPA Sublingual gland 7 (4+3) 7 (4+3) 26 pT2N0M0
89 F 24 CXPA Parotid 7 (4+3) 7 (4+3) 97 pT2N0M0
90 M 42 CXPA Parotid 8 (5+3) 7 (4+3) 55 R (10) N (10) pT1N0M0
91 M 43 CXPA Parotid 6 (3+3) 7 (4+3) 63 pT3N0M0
92 M 72 CXPA Parotid 7 (4+3) 6 (3+3) 166 pT2NxM0
93 F 89 CXPA Parotid 6 (3+3) 6 (3+3) 151 pT3NxM0
94 M 50 CXPA Parotid 7 (4+3) 7 (4+3) 166 pT2N0M0
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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The cases for which PAP-stained slides were re-used for
immunocytochemical evaluation of CAF-1/p60 were all PA
(15 cases, parotid gland; 5 cases, submandibular gland; 3
cases, minor salivary glands, Fig. 1G).
During follow-up (mean 100.02 months, median 90.5
months, range 13-203 months), 5 patients (1.9%) developed
a CXPA. In three cases, the baseline tumour was a PA of the
parotid gland, and in the remaining two cases atypical PA of
minor salivary glands.
Malignant SGT. The malignant SGT consisted of 21 cases of
adenoid cystic carcinomas (ACC), 2 polymorphous-low grade
adenocarcinomas (PLGC), 14 acinic cell carcinomas (AC),
49 muco-epidermoid carcinomas (MEC: 22 low-grade, 14
intermediate-grade and 13 high-grade tumours) and 8 cases
of carcinoma ex-PA (CXPA). The clinical features of all the
tumours are reported in Table II.
During follow-up (mean 92.56 months, median 92.5
months, range 12-200 months) 6 patients (6.38%) had
recurrence of the tumour (1PLGC, 1AC, 1ACC, 3MEC), 1
(1.06%) recurrence and nodal metastasis (1CXPA), 1 (1.06%)
recurrence and distant metastasis (1ACC) and 3 (3.19%)
distant metastasis (3 MEC).
Immunohistochemistry
CAF-1/p60 expression in benign SGT. The large majority of
benign SGT (264 cases, 98.51%) showed a quickscore 5 of
immunostaining for CAF-1/p60 (Fig. 1A and B). Only 4 cases
(1.55%; all PA, two of the ordinary type and two atypical),
which showed malignant transformation (CXPA) during
follow-up, presented instead a quickscore 6 (Fig. 1C-F)
(Table I).
The cytological smears concerned cases of PA which
showed, on histological sections, a quickscore 5 in 20 cases
and a score 6 in 3 cases which progressed to CXPA (Fig. 1G).
Immunocytochemistry showed clusters of neoplastic cells
strongly positive for the protein only in these 3 cases (Fig. 1H).
ki67/MIB1 expression in benign SGT. In the majority of benign
SGT (231 out 268, 86.20%), a quickscore 3 of ki67/MIB1
expression was found; 20 cases (7.46%) showed a quickscore
4 and the remaining 17 cases (6.34%) a quickscore 5.
Among the cases which progressed toward malignancy
during the follow-up, the quickscore was, respectively: 3 in 1
case, 4 in 2 cases and 5 in 2 cases (Table I).
CAF-1/p60 expression in malignant SGT. Overall, the
quickscore for CAF-1/p60 expression ranged from 6 to 9 in
malignant SGT (6-8 in AC, 6-9 in ACC, 6-7 in low-grade
MEC, 6-9 in intermediate-grade MEC, 6-8 in high grade
MEC, CXPA and PLGA).
The cases that recurred or progressed to nodal and/or
distant metastases, showed always a quickscore 8-9 for
CAF-1/p60 (Table II, Fig. 2A-E).
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Figure 2. CAF-1/p60 overexpression in malignant SGT (LSAB-HRP, nuclear counterstaining with haematoxylin). Strong immunostaining for CAF-1/p60 in
metastasizing malignant SGT: AC (A, x106), CXPA (B, x106), ME (C, x106), PLGA (D, x106). Metastasizing ACC: the same case showed strong expression
for CAF-1/p60 (E, x150), and moderate expression for ki67/MIB1 (F, x150).
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ki67/MIB1 expression in malignant SGT. The quickscore for
ki67/MIB1 in malignant SGT ranged from 4 to 7 (AC:
quickscore 4; ACC: 4-6; low-grade MEC: 4-5; intermediate-
and high-grade MEC: 5-6; CXPA: 6-7; PLGC: 3). The
recurrent and/or metastasizing cases showed a quickscore
between 3 and 7 (Table II, Fig. 2F).
Expression of CAF-1/p60 and ki67/MIB1 in normal salivary
glands. The residual normal salivary glands surrounding
either benign and malignant SGT showed a quickscore 2 for
ki67/MIB1 and 2-3 for CAF-1/p60.
Statistical analysis
K-statistics. The level of agreement of the evaluation of the
quickscore of both CAF-1/p60 and ki67/MIB1, expressed by
the K-coefficient, was 0.8 (excellent agreement) for both
intra- and inter-observer evaluations, respectively.
Factors predicting development of cancer in patients with
benign tumour baseline. According to univariate analysis,
cancer onset was significantly related to: ki67/MIB1 expres-
sion (p<0.0001) and CAF-1/P60 (p<0.0001). Cox's multiple
regression analysis selected CAF-1/p60 expression as the best
independent and significant predictor of cancer development
(p<0.0001).
Factors predicting disease-free intervals in patients with
malignant tumour baseline. According to univariate analysis,
the recurrence of tumour was significantly related to: female
gender (p<0.05), ki67/MIB1 (p<0.0002) and CAF-1/p60
(p<0.0001). Applying Cox's multiple regression analysis,
CAF-1/p60 expression (p<0.002) and staging (p<0.001) were
the best set of covariates significantly predicting recurrence
of the disease.
Concerning the occurrence of distant metastases, the
univariate analysis showed that the expression of ki67/MIB1
(p<0.001), CAF-1/p60 (p<0.0001) and staging (p<0.0001)
were significantly related to the metastasis development.
Cox's multiple regression analysis selected CAF-1/p60 as the
best independent predictor of metastasis onset (p<0.0004).
Clinical usefulness of CAF-1/p60 index. To further evaluate
the usefulness of the CAF-1/p60 expression in the prediction
of cancer development in patients who had a baseline benign
tumour, sensitivity and specificity were calculated for each
point of the quickscore, and receiver operating characteristic
(ROC) curves were drawn. The best discriminant point of
CAF-1/p60 quickscore was 5, which had 80% sensitivity and
100% specificity, and the calculated area under curve
corresponded to 0.9 (Fig. 3).
A similar analysis was performed to evaluate the useful-
ness of CAF-1/p60 in the prediction of an adverse event
(recurrence, or nodal or distant metastasis) in patients who
had a baseline malignant tumour. Sensitivity and specificity
in predicting both recurrence of disease and metastasis, were
calculated for each point of the quickscore, and ROC curves
were drawn. The best discriminative point of CAF-1/p60
quickscore predicting both recurrence of disease or metastasis
risk was 7, which showed 100% sensitivity and 93%
specificity in predicting recurrence of a tumour, and 100%
sensitivity and 89% specificity in predicting metastasis.
Calculated areas under curve were 0.96 for the prediction of
disease recurrence and 0.97 for prediction of metastasis,
respectively (Fig. 3).
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Figure 3. Receiver operating characteristic curves: (A) prediction of cancer
development according to CAF-1/p60 immunopattern; (B) prediction of
disease recurrence according to CAF-1/p60 immunopattern; (C) prediction
of metastasis occurrence according to CAF-1/p60 immunopattern.
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Discussion
Salivary gland neoplasms comprise the most heterogeneous
group of tumours of any body site, with frequent overlap of
histological parameters and biological outcome (1,2,28,29).
Efforts to identify biomarkers able to assist in the differential
diagnosis of these tumours and in predicting their evolution
did not provide conclusive results (29-31).
Recent studies evidenced that epigenetic alterations may
play a role in the development and progression of SGT (32-35).
However, a relatively limited variety of SGT histotypes and
genes analyzed for epigenetic regulation has been examined
(36). The assembly and remodelling of chromatin are among
the most important epigenetic modifications, in eukaryotic
cells (37).
CAF-1 promotes the first step of nucleosome assembly
in replicating DNA. The expression of CAF-1/p60 subunit
directly correlates with cell proliferation in normal and neo-
plastic cells. This seems particularly attractive for researchers
facing with SGT, considering that cell proliferation is one of
the few proposed prognostic parameters for most of these
tumours. The large majority of reports on this topic concern
the immunohistochemical evaluation of the proliferating cell
compartment by the ki67/MIB1 antibody.
The methodological approaches to this evaluation differed
considerably among researchers. In particular, the evaluated
ki67/MIB1 stained cells ranged from 500 to 1000, randomly
scored either with or without the aid of a video-scaler, or
from the densest area of immunopositive cancer cells for mm2
of tumour tissue (4,11,12).
These discrepancies and the frequently small retro-
spective series studied, due to the rarity of SGT, may explain
the questionable results concerning the clinical value of ki67/
MIB1-stained cell fraction in evaluating the biological
behaviour of SGT.
A correlation between a high ki67/MIB1 labelling index
and the unfavourable prognosis of MEC has been reported,
but for ACC some studies found ki67/MIB1 useful for
predicting the biologic behaviour and/or treatment failure,
while others found it not associated with morphology or
clinical course of patients (6,10,11,38).
Moreover, for AC, a study showed that most patients with
tumour ki67/MIB1 indices above 10% had unfavourable
outcomes, whereas other reports evidenced overlap of indices
between favourable and worse outcomes or showed that
ki67/MIB1 revealed of statistical value in predicting tumour
outcome (7,39).
For PLGA, the ki67/MIB1 index was generally not found
useful in predicting clinical behaviour and, in particular,
Lazzaro and Cleveland showed that for PA, PLGA and ACC,
the ki67/MIB1 score is not related either to the benign or
malignant nature of tumours or to their specific clinical course
(6,40-42).
For benign SGT, it has been stated that a moderate
mitotic activity and older patient age, large tumour size and
the occurrence in the submandibular gland, are associated
to a greater likelihood of malignant transformation (43).
However, a recent study evidenced that proliferation markers
did not reveal significant differences between morpho-
logically benign metastasizing PA and a control group of
conventional PA (44).
Finally, the ki67/MIB1 index was thought either of
overall utility in predicting the clinical behaviour of SGT, or
it was considered significant only when coupled to TUNEL
evaluation and p53 staining (4,12,45).
Therefore, as it has recently emerged also for other
malignant tumours, unresolved questions concerning the role
of ki67/MIB1 as a real independent marker of prognosis
for the major histotypes of malignant SGT still need to be
answered.
Moreover, it has to be clarified whether this proliferation
marker has the potential to detect early the cases of benign
tumours which are trans-differentiating toward a malignant
phenotype. It is still uncertain whether ki67/MIB1 is the best
proliferation-associated predictor of malignancy and
aggressiveness for SGT.
In this study, we decided to score an entire histological
section of each SGT for ki67/MIB1 and CAF-1/p60
expression, evaluating them according to the ‘quickscore’
method, which is easy to perform by pathologists in addition
to the routine diagnostic analysis. We found CAF-1/ p60
always expressed, in benign as in malignant SGT, with the
highest degree of overexpression in more aggressive cases.
This was in-line with the reported association between the
hyper-expression of the protein and the deregulation of the
cell proliferation in malignant tumours of breast, tongue and
prostate and in malignant melanoma, and was extremely
significant in terms of statistical evaluation, besides tumour
histotype, grade and stage at diagnosis (18,20).
The overexpression of CAF-1/p60 may be then consi-
dered an overall hallmark of malignancy for SGT, which
may assist in the challenging differential diagnosis between
benign and malignant SGT. Moreover, the protein shows
further significance in discriminating the cases of malignant
SGT with metastatic ability.
Interesting considerations emerge also by the finding, in
the majority of PA followed by the occurrence of CXPA
after surgery, of a CAF-1/p60 quickscore higher than in non-
progressed benign SGT, with aggregates of neoplastic cells
strongly positive for CAF-1/p60 in the corresponding FNAB
preoperative samples of some of these cases.
In our opinion, CAF-1/p60 is highly effective to early
identify the cases of benign epithelial salivary gland tumours
which are trans-differentiating toward a malignant pheno-
type. This sounds particularly attractive for the evaluation
of the biological behaviour of the clinically benign PA with
‘bizarre/atypical’ features, which sometimes may show an
aggressive biological course, and of even greater importance
for the cases of the classical form of PA, which rarely may
evolve toward malignancy, in a manner unpredictable upon
the classical histological and cytological parameters (46-48).
To date, this is the first study addressing the role of the
expression of CAF-1/p60 in predicting the outcome of patients
with SGT.
Considering the rarity of these tumours, we believe that
our single institution's series of cases, for number, histotype
of lesions and length of follow-up, may be considered adequate
to evaluate the biological significance of the expression of
CAF-1/p60 in SGT.
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Our results emphasize the role of epigenetic changes in
SGT, and evidence a pivotal role for CAF-1/p60 as a marker
of aggressiveness, with an additional value with respect to
ki67/MIB1 in predicting the outcome of malignant SGT and
improving the chances of early diagnosis of the subclass of
benign SGT trans-differentiating toward malignancy. The
utilization of the quickscore takes about 15 min per case, and
appears of potential great utility for routine use for patho-
logists. Moreover, the appreciable immunostaining for the
protein on FNAB samples, gives an additional chance of a
preoperative ‘biological’ screening of patients with PA.
For therapeutic purposes, it has to be remembered that, up
to date, neither conventional chemotherapy, nor the existing
targeted drugs have shown satisfactory results against these
tumours (49). The ultimate significance of our results in bio-
logical terms still needs to be definitely understood.
Nevertheless, they encourage us to hypothesize a role for
CAF-1/p60 as a promising molecular target for therapies
tailored to reverse this epigenetic alteration in aggressive SGT.
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